Everest Organics has allotted 2.63 lakh shares worth ₹4 crore to its Managing Director and Promoter, Dr. Sri Kakarlapudi Sirisha. This follows the conversion of convertible warrants and injects capital into the company.
Everest Organics Allots ₹4 Crore Shares to Promoter
Everest Organics Limited has completed the allotment of 2,63,157 equity shares to its Managing Director and Promoter, Dr. Sri Kakarlapudi Sirisha, following the conversion of convertible warrants. The total consideration for this allotment is ₹4.00 crore.
Reader Takeaway: Promoter commitment via share allotment; Capital infusion bolsters company finances, but shares face a lock-in.
What just happened
The company has formally allotted 2,63,157 fully paid-up equity shares to Dr. Sri Kakarlapudi Sirisha, who is both the Managing Director and a Promoter.
This allotment is a result of the conversion of convertible warrants that were initially issued in January 2025.
The decision was approved by the Board of Directors through a resolution by circulation on July 11, 2026.
Why this matters
This transaction brings a capital infusion of ₹4.00 crore into Everest Organics Limited.
The company received the remaining 75% of the payment, amounting to ₹3.00 crore, at the time of warrant conversion.
The shares were issued at ₹152 each, comprising a face value of ₹10 and a share premium of ₹142.
The backstory
The convertible warrants were originally issued in January 2025.
This allotment marks the successful culmination of a capital-raising plan initiated in early 2025.
What changes now
The newly allotted shares are identical in rights to the company's existing equity shares (pari-passu).
However, these shares are subject to an 18-month lock-in period, starting from the date they receive trading approval from the BSE.
The company is now required to apply to the BSE for listing and trading approval of these 2,63,157 shares.
Risks to watch
The primary risk is the eventual dilution of existing shareholders' equity once the lock-in period expires and the promoter can trade these shares.
Peer comparison
No direct peer comparison is available from the filing.
Context metrics (time-bound)
Convertible warrants were issued in January 2025.
Board approval for allotment was on July 11, 2026.
Total consideration is ₹4.00 crore.
Lock-in period is 18 months from trading approval.
What to track next
Investors should monitor the BSE's approval for listing and trading of these new shares.
Tracking the utilization of the ₹4.00 crore capital infusion by Everest Organics for its business operations will be crucial.